Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 5;14(1):8061.
doi: 10.1038/s41598-024-58616-4.

Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis

Jianfang Zhu  1 , Ke Yuan  1 , Sunita Rana  2 , Satya Lavanya Jakki  2 , Amit Subray Bhat  2 , Li Liang  1 , Chunlin Wang  3
Affiliations

Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis

Jianfang Zhu et al. Sci Rep. .

Abstract

The purpose of this study is to compare the relative efficacy and safety of long-acting growth hormone (LAGH) as a growth hormone replacement therapy in prepubertal children with growth hormone deficiency (GHD). We searched the PubMed, Embase, CNKI, and Wanfang databases from inception to July 2023 and identified eleven relevant studies. PEG-LAGH showed better effect on height velocity (mean difference [MD]: - 0.031, 95% credibility interval [CrI]: - 0.278, 0.215) than somatrogon (MD: 0.105, 95% CrI: - 0.419, 0.636), somapacitan (MD: 0.802, 95% CrI: - 0.451, 2.068) and lonapegsomatropin (MD: 1.335, 95% CrI: - 0.3, 2.989) when compared with daily growth hormone (DGH). Furthermore, in terms of height standard deviation score, PEG-LAGH demonstrated better improvement (MD: - 0.15, 95% CrI: - 1.1, 0.66) than somatrogon (MD: - 0.055, 95% CrI: - 1.3, 0.51) and somapacitan (MD: 0.22, 95% CrI: - 0.91, 1.3). PEG-LAGH (risk ratio [RR]: 1.00, 95% CrI: 0.82, 1.2) reduced the risk of adverse events compared with other LAGH (somatrogon, RR: 1.1, 95% CrI: 0.98, 1.2; somapacitan, RR: 1.1, 95% CrI: 0.96, 1.4; lonapegsomatropin, RR, 1.1, 95% CrI: 0.91, 1.3) and was comparable with DGH. This is the first study to indirectly compare the LAGH thorough a network meta-analysis and provide evidence of the optimal efficacy of various LAGH specifically PEG-LAGH and acceptable safety profile in prepubertal children with GHD.

Keywords: Growth hormone; Growth hormone deficiency; Height velocity; Long-acting growth hormones; Short stature.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
PRISMA flow chart.
Figure 2
Figure 2
Forest plot comparing HV between LAGH and DGH. CrI credible interval; GH growth hormone; HV height velocity; LAGH long-acting growth hormone.
Figure 3
Figure 3
Forest plot comparing HSDS between LAGH and DGH. CrI credible interval; GH growth hormone; HSDS height standard deviation score; LAGH long-acting growth hormone.
Figure 4
Figure 4
Forest plot comparing AEs between LAGH and DGH. AEs adverse events; CrI credible interval; GH growth hormone; LAGH long-acting growth hormone.
See this image and copyright information in PMC

References

    1. Ranke MB. Short and long-term effects of growth hormone in children and adolescents with GH deficiency. Front. Endocrinol. 2021;12:720419. doi: 10.3389/fendo.2021.720419. - DOI - PMC - PubMed
    1. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J. Clin. Endocrinol. Metab.85, 3990–3993 (2000). - PubMed
    1. Richmond E, Rogol AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract. Res. Clin. Endocrinol. Metab. 2016;30:749–755. doi: 10.1016/j.beem.2016.11.005. - DOI - PubMed
    1. Collett-Solberg, P. F. et al. Growth hormone therapy in children; research and practice—A review. Growth Horm. IGF Res.44, 20–32 (2019). - PubMed
    1. Slattery M, Bredella MA, Stanley T, Torriani M, Misra M. Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls. Int. J. Pediatr. Endocrinol. 2014;2014:22. doi: 10.1186/1687-9856-2014-22. - DOI - PMC - PubMed

Publication types

MeSH terms